Lorinda S Chung, MD

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

10 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chung’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

10 of 10 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A76014 · Current

Licensed to practise in California · since 2001 · expires 2027-08-31 · Ohio State University College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$24,321

Medicare paid this office $24,321 for 103 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	53	$9,941	$133
Return visit (30+ min)	28	$3,128	$92
New patient visit (60+ min)	16	$2,759	$172
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$2,621	$154
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	66	$1,336	$15

See all 6 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	53	$9,941	$133
Return visit (30+ min)	28	$3,128	$92
New patient visit (60+ min)	16	$2,759	$172
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$2,621	$154
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	66	$1,336	$15
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	20	$792	$27

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Removal of skin lesions	1-10	None

Who their Medicare patients are

103 Original Medicare patients in 2024. Average age 68 · Under 65 27% · Women 80% · Also on Medicaid 27% · Health risk score 1.95. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.

Conditions among them: High blood pressure 56% · Chronic kidney disease 28% · Coronary heart disease 27% · Heart failure 23% · Atrial fibrillation 22% · Depression 21% · COPD 20% · Diabetes 19% · Cancer 16%.

The office billed $95,853, Medicare allowed $31,557 and paid $24,321; for 302 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	103	302	68	1.95	$95,853	$24,321
2023	87	148	68	2.31	$52,193	$15,685
2022	82	140	70	1.98	$55,135	$15,397
2021	70	140	68	1.86	$58,830	$15,366
2020	57	88	66	2.04	$37,907	$7,563
2019	67	115	67	2.23	$20,525	$10,053
2018	133	240	65	2.14	$50,177	$23,615
2017	112	202	66	2.19	$49,801	$19,498
2016	110	200	66	1.82	$60,175	$19,214
2015	85	144	66	1.73	$39,610	$13,474
2014	97	202	65	2.08	$60,075	$19,041
2013	86	172	65	1.85	$46,535	$14,878

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	45	$7,728	$127
Return visit (30+ min)	26	$2,754	$81
New patient visit (60+ min)	12	$1,643	$137
Return visit (30+ min)	12	$1,084	$83

2022: 3 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	35	$6,562	$119
Return visit (30+ min)	24	$2,446	$82
New patient visit (60+ min)	13	$2,141	$165

2021: 3 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	31	$5,283	$117
Return visit (30+ min)	27	$3,194	$86
New patient visit (60+ min)	17	$2,826	$166

2020: 3 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	33	$2,814	$63
Long return visit (40+ min)	22	$2,205	$88
New patient visit (60+ min)	12	$1,845	$154

2019: 2 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	34	$4,604	$96
Return visit (30+ min)	32	$2,509	$60

2018: 5 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	100	$14,009	$92
New patient visit (60+ min)	23	$3,245	$141
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	13	$3,183	$94
Initial hospital care with moderate level of medical decision making at least 75 minutes	11	$2,001	$182
Return visit (30+ min)	12	$781	$65

2017: 2 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	93	$14,500	$92
New patient visit (60+ min)	18	$2,664	$148

2016: 3 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	79	$12,040	$93
New patient visit (60+ min)	19	$2,553	$134
Return visit (30+ min)	17	$1,111	$53

2015: 3 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	45	$6,534	$98
Return visit (30+ min)	31	$2,984	$66
New patient visit (60+ min)	17	$2,417	$142

2014: 5 services

Sort by

Original Medicare services billed in 2014

Long return visit (40+ min)	40	$5,712	$92
Return visit (30+ min)	38	$4,196	$68
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$3,697	$92
Initial hospital care with moderate level of medical decision making at least 75 minutes	16	$2,878	$180
New patient visit (60+ min)	15	$2,246	$150

2013: 3 services

Sort by

Original Medicare services billed in 2013

Long return visit (40+ min)	48	$6,751	$87
New patient visit (60+ min)	26	$3,671	$141
Return visit (30+ min)	37	$3,396	$65

Drugs they prescribed that Part D paid

$158,125

Pharmacies billed $158,125 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 204) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.

180 generic and 24 brand-name prescriptions · $158,125 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Sildenafil Citrate	27	$2,006	$74
Hydroxychloroquine Sulfate	22	$1,149	$52
Escitalopram	12	$152	$13
Prednisone	17	$96	$6

Year by year

Sort by

Part D prescribing by year

2024	204	42	0% (0)	12%	$158,125
2023	271	36	0% (0)	9%	$175,907
2022	185	35	None	None	$131,055
2021	159	32	0% (0)	16%	$77,018
2020	183	32	0% (0)	15%	$123,520
2019	320	53	None	9%	$126,925
2018	582	72	None	11%	$206,145
2017	534	65	None	5%	$57,934
2016	411	55	None	10%	$31,557
2015	312	36	None	9%	$26,823
2014	271	35	None	9%	$46,457
2013	318	35	None	10%	$53,473

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Sort by

Part D drugs prescribed in 2023

Sildenafil Citrate	33	$5,441	$165
Mycophenolate Mofetil	13	$2,318	$178
Hydroxychloroquine Sulfate	26	$1,731	$67
Leflunomide	14	$869	$62
Prednisone	35	$337	$10
Meloxicam	18	$148	$8
Escitalopram	20	$133	$7
Alendronate	11	$127	$12

2022: 4 drugs

Sort by

Part D drugs prescribed in 2022

Mycophenolic Acid	12	$17,251	$1,438
Sildenafil Citrate	23	$7,220	$314
Hydroxychloroquine Sulfate	26	$2,319	$89
Prednisone	18	$240	$13

2021: 4 drugs

Sort by

Part D drugs prescribed in 2021

Benlysta	11	$46,805	$4,255
Hydroxychloroquine Sulfate	19	$1,437	$76
Sildenafil Citrate	18	$820	$46
Prednisone	13	$162	$12

2020: 6 drugs

Sort by

Part D drugs prescribed in 2020

Benlysta	12	$47,706	$3,976
Hydroxychloroquine Sulfate	15	$1,825	$122
Pentoxifylline	11	$711	$65
Nifedipine Er	18	$662	$37
Methotrexate	14	$479	$34
Prednisone	20	$297	$15

2019: 9 drugs

Sort by

Part D drugs prescribed in 2019

Sildenafil Citrate	27	$49,225	$1,823
Hydroxychloroquine Sulfate	42	$4,140	$99
Mycophenolate Mofetil	18	$2,924	$162
Celecoxib	15	$914	$61
Nifedipine Er	19	$679	$36
Omeprazole	19	$611	$32
Escitalopram	22	$377	$17
Prednisone	22	$340	$15
Pantoprazole	18	$147	$8

2018: 13 drugs

Sort by

Part D drugs prescribed in 2018

Sildenafil	61	$53,560	$878
Hydroxychloroquine Sulfate	72	$8,520	$118
Mycophenolate Mofetil	33	$4,465	$135
Mitigare	12	$4,230	$353
Celecoxib	13	$1,083	$83
Nifedipine Er	27	$1,030	$38
Prednisone	91	$942	$10
Methotrexate	12	$734	$61
Omeprazole	30	$650	$22
Pantoprazole	29	$303	$10
Ranitidine	16	$292	$18
Escitalopram	18	$255	$14
Alendronate	11	$163	$15

2017: 15 drugs

Sort by

Part D drugs prescribed in 2017

Sildenafil	60	$29,231	$487
Hydroxychloroquine Sulfate	60	$8,775	$146
Mycophenolate Mofetil	49	$5,191	$106
Celecoxib	25	$3,606	$144
Methotrexate	18	$854	$47
Nifedipine Er	14	$643	$46
Pantoprazole	23	$585	$25
Omeprazole	37	$584	$16
Prednisone	53	$558	$11
Baclofen	12	$167	$14
Escitalopram	15	$148	$10
Alendronate	29	$136	$5
Ranitidine	13	$128	$10
Amlodipine Besylate	16	$59	$4
Lisinopril	18	$36	$2

2016: 12 drugs

Sort by

Part D drugs prescribed in 2016

Sildenafil	36	$8,916	$248
Hydroxychloroquine Sulfate	28	$4,169	$149
Mycophenolate Mofetil	38	$3,558	$94
Leflunomide	15	$2,177	$145
Prednisone	44	$704	$16
Celecoxib	11	$635	$58
Omeprazole	32	$509	$16
Methotrexate	24	$481	$20
Pantoprazole	18	$370	$21
Triamcinolone Acetonide	15	$220	$15
Meloxicam	21	$110	$5
Alendronate	23	$92	$4

2015: 9 drugs

Sort by

Part D drugs prescribed in 2015

Mycophenolate Mofetil	41	$6,433	$157
Hydroxychloroquine Sulfate	27	$5,517	$204
Sildenafil	27	$2,651	$98
Omeprazole	32	$1,214	$38
Prednisone	32	$557	$17
Escitalopram	17	$309	$18
Pantoprazole	11	$195	$18
Triamcinolone Acetonide	13	$172	$13
Allopurinol	11	$54	$5

2014: 10 drugs

Sort by

Part D drugs prescribed in 2014

Sildenafil	25	$19,150	$766
Colcrys	12	$5,887	$491
Mycophenolate Mofetil	25	$4,172	$167
Hydroxychloroquine Sulfate	26	$1,245	$48
Methotrexate	13	$824	$63
Pantoprazole	21	$336	$16
Omeprazole	21	$293	$14
Triamcinolone Acetonide	15	$188	$13
Prednisone	18	$187	$10
Allopurinol	16	$81	$5

2013: 8 drugs

Sort by

Part D drugs prescribed in 2013

Sildenafil	23	$35,678	$1,551
Mycophenolate Mofetil	18	$2,479	$138
Hydroxychloroquine Sulfate	51	$1,146	$22
Cilostazol	16	$705	$44
Omeprazole	30	$511	$17
Pantoprazole	25	$338	$14
Prednisone	17	$160	$9
Amlodipine Besylate	11	$73	$7

Money from drug and device companies

$3,200 in 2025

Sort by

Industry payments by year

2025	3	3	$3,200	$3,200
2024	3	6	$2,560	$3,610
2023	1	1	$1,600	$1,600
2022	4	6	$5,438	$5,438
2021	1	2	$1,000	$1,000
2020	3	19	$6,747	$8,812
2019	4	15	$13,803	$14,666

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Abbvie	None	$1,950	1 payment Consulting · 2025-05-06 · $1,950
Amgen	Blincyto	$800	1 payment Consulting for Blincyto · 2025-11-25 · $800
Genentech	None	$450	1 payment Consulting · 2025-03-26 · $450

See all 3 published payments

Sort by

Every published payment

Amgen	Consulting · 2025-11-25	Blincyto	$800
Abbvie	Consulting · 2025-05-06	None	$1,950
Genentech	Consulting · 2025-03-26	None	$450

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $3,610

Sort by

Payments by company in 2024

Boehringer Ingelheim Pharmaceuticals	None	$2,526	3 payments Consulting · 2024-12-17 · $1,960 Travel · 2024-12-09 · $432 Meals · 2024-11-13 · $134
Genentech	None	$600	1 payment Consulting · 2024-01-18 · $600
Abbvie	None	$483	2 payments Travel · 2024-12-23 · $432 Meals · 2024-11-14 · $51

2023: $1,600

Sort by

Payments by company in 2023

Eli Lilly and	None	$1,600	1 payment Consulting · 2023-09-25 · $1,600

2022: $5,438

Sort by

Payments by company in 2022

Mitsubishi Tanabe Pharma Development America	None	$2,400	2 payments Consulting · 2022-07-08 · $1,200 Consulting · 2022-04-28 · $1,200
Actelion Pharmaceuticals US	Opsumit	$1,550	1 payment Consulting for Opsumit · 2022-12-16 · $1,550
Genentech	None	$1,150	2 payments Consulting · 2022-10-24 · $150 Consulting · 2022-07-27 · $1,000
Boehringer Ingelheim Pharmaceuticals	Ofev	$338	1 payment Paid to speak or teach for Ofev · 2022-12-20 · $338

2021: $1,000

Sort by

Payments by company in 2021

Genentech	None	$1,000	2 payments Consulting · 2021-08-19 · $500 Consulting · 2021-03-09 · $500

2020: $8,812

Sort by

Payments by company in 2020

Boehringer Ingelheim Pharmaceuticals	Ofev	$7,401	12 payments Education · 2020-10-12 · $7 Education · 2020-07-23 · $7 Consulting for Ofev · 2020-02-19 · $5,450 Meals for Ofev · 2020-02-19 · $35 Travel for Ofev · 2020-02-19 · $140 Meals for Ofev · 2020-01-23 · $19 Travel for Ofev · 2020-01-23 · $1,231 Meals for Ofev · 2020-01-23 · $71 Meals for Ofev · 2020-01-23 · $137 Meals for Ofev · 2020-01-23 · $50 Meals for Ofev · 2020-01-23 · $40 Travel for Ofev · 2020-01-23 · $213
Boehringer Ingelheim International GmbH	Ofev	$1,297	4 payments Paid to speak or teach for Ofev · 2020-10-25 · $391 Paid to speak or teach for Ofev · 2020-08-27 · $184 Paid to speak or teach for Ofev · 2020-06-04 · $506 Paid to speak or teach for Ofev · 2020-03-30 · $217
Amgen	Enbrel	$114	3 payments Meals · 2020-02-25 · $17 Meals for Prolia · 2020-01-23 · $16 Meals for Enbrel · 2020-01-07 · $81

2019: $14,666

Sort by

Payments by company in 2019

Boehringer Ingelheim Pharmaceuticals	Ofev	$9,449	8 payments Meals for Ofev · 2019-12-09 · $35 Consulting for Ofev · 2019-12-09 · $8,550 Travel for Ofev · 2019-12-09 · $140 Travel for Ofev · 2019-11-11 · $315 Meals for Ofev · 2019-11-10 · $16 Paid to speak or teach for Ofev · 2019-05-17 · $84 Paid to speak or teach for Ofev · 2019-05-17 · $194 Meals · 2019-01-08 · $115
Boehringer Ingelheim International GmbH	Ofev	$2,937	2 payments Consulting for Ofev · 2019-12-05 · $2,900 Travel for Nintedanib · 2019-12-05 · $37
Mitsubishi Tanabe Pharma Development America	None	$2,075	1 payment Consulting · 2019-03-29 · $2,075
Amgen	Enbrel	$205	4 payments Meals for Evenity · 2019-12-03 · $47 Meals for Prolia · 2019-10-29 · $41 Meals · 2019-08-28 · $42 Meals for Enbrel · 2019-06-27 · $76

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Boehringer Ingelheim Pharmaceuticals, Inc. · Detection and Management of Ild in Connective Tissue Disease · 2024	Their institution	$248,396
Boehringer Ingelheim Pharmaceuticals, Inc. · Validation of A Highly Sensitive Lung Ultrasound I · 2020	Their institution	$150,000
GlaxoSmithKline, LLC. · A Multi-Centre, Randomized, Double-Blind (Sponsor Open), Placebo-Contr · 2019	Their institution	$84,569
MITSUBISHI TANABE PHARMA AMERICA, INC. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate Efficacy, Safety, and Tolerability of Mt-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis · 2023	Their institution	$83,087
Boehringer Ingelheim Pharmaceuticals, Inc. · Validation of A Highly Sensitive Lung Ultrasound I · 2021	Their institution	$75,000
Kadmon Corporation LLC · A Phase 2 Randomized Placebo Controlled Double Blind Open Label Extension Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Diffuse Cutaneous Systemic Sclerosis · 2021	Their institution	$60,148
United Therapeutics Corporation · A Pilot Study To Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis · 2019	Their institution	$54,387
United Therapeutics Corporation · Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis · 2022	Their institution	$49,441
Amgen Inc. · P2b Hzn-825-301 Dcssc Beacon · 2024	Their institution	$30,247
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate Efficacy, Safety, and Tolerability of Mt-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis · 2022	Their institution	$29,640
Horizon Therapeutics plc · A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Trial To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Hzn-825 in Patients With Diffuse Cutaneous Systemic Sclerosis · 2023	Their institution	$28,703
GlaxoSmithKline, LLC. · A Multi-Centre, Randomized, Double-Blind (Sponsor Open), Placebo-Contr · 2020	Their institution	$25,306
Bayer HealthCare Pharmaceuticals Inc. · Bay63-2521 Systemic Sclerosis Placebo · 2019	Their institution	$23,580
Amgen Inc. · A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Trial To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Hzn-825 in Patients With Diffuse Cutaneous Systemic Sclerosis · 2025	Their institution	$18,938
Amgen Inc. · A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Trial To Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Hzn-825 in Patients With Diffuse Cutaneous Systemic Sclerosis · 2025	Their institution	$16,542
GlaxoSmithKline, LLC. · A Multi-Centre, Randomized, Double-Blind (Sponsor Open), Placebo-Contr · 2022	Their institution	$16,160
Kadmon Corporation LLC · A Phase 2, Randomized, Placebo Controlled, Double-Blind, Open-Label Extension Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Diffuse Cutaneous Systemic Sclerosis · 2020	Their institution	$15,756
SANOFI US SERVICES INC. · A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Open-Label Extension Multicenter Study To Evaluate the Efficacy and Safety of Belumosudil (Kd025) in Subjects With Diffuse Cutaneous Systemic Sclerosis · 2023	Their institution	$15,142
GlaxoSmithKline, LLC. · A Multi-Centre, Randomized, Double-Blind (Sponsor Open), Placebo-Contr · 2021	Their institution	$6,040
MITSUBISHI TANABE PHARMA AMERICA, INC. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate Efficacy, Safety, and Tolerability of Mt-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis · 2024	Their institution	$2,519
Boehringer Ingelheim International GmbH · Conquest: Bi 1015550 in A Platform Trial in Ssc-Ild (Srf) · 2024	Their institution	$2,458
Amgen Inc. · P2b Hzn-825-301 Dcssc Beacon · 2025	Their institution	$2,287

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1427026442
Licence: CA A76014California A76014: Current · expires 2027-08-31
Trained: Ohio State University College of Medicine, 2000
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
Mailing address: 300 Pasteur Dr, Palo Alto, CA, 94304
NPI first listed: 2006-03-08
NPI last updated: 2024-04-28
NPI record certified: 2024-04-28

This is when the NPI record was last certified, not a medical board exam.